Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CT-044 HCl multiple-dose escalation in healthy volunteers
NCT04175743Phase 1Unknown
- Sponsor
- Lotus Clinical Research
- Start
- Dec 2019
- Primary completion
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of CT-044 in acute pain and neuropathy (3 cohorts), sponsored by Lotus Clinical Research. Primary endpoints: Maximum exposure level of CT-044 at 49 days, Plasma Pharmacokinetic Concentration of CT-044 at 32 hours and 1 more. Status: unknown.
02
Drugs
CT-044
03
Conditions
acute painneuropathy
Beyond the preview
Go deeper on NCT04175743.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04175743.